Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer
JW Welsh, R Komaki, A Amini, MF Munsell… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …
EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases
J Zhao, X Ye, Y Xu, M Chen, W Zhong, Y Sun… - Cancer chemotherapy …, 2016 - Springer
Purpose Central nervous system (CNS) is the prevalent site for metastases in epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-relapsed NSCLC patients. To …
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-relapsed NSCLC patients. To …
EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases
D Luo, X Ye, Z Hu, K Peng, Y Song, X Yin, G Zhu, Q Ji… - Tumor Biology, 2014 - Springer
Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …
EGFR mutation status in brain metastases of non-small cell lung carcinoma
F Burel-Vandenbos, D Ambrosetti, M Coutts… - Journal of neuro …, 2013 - Springer
Brain metastases are a frequent and grave complication of non-small cell lung carcinoma
(NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and …
(NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and …
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and …
M Hochmair - Targeted Oncology, 2018 - Springer
Brain metastases and/or leptomeningeal disease (LMD) with associated central nervous
system (CNS) metastases are known complications of advanced epidermal growth factor …
system (CNS) metastases are known complications of advanced epidermal growth factor …
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
T Iuchi, M Shingyoji, T Sakaida, K Hatano, O Nagano… - Lung cancer, 2013 - Elsevier
Background Brain metastases (BM) are a common in patients with lung cancer. Although
whole-brain radiation therapy (WBRT) is the standard therapy, it may have a risk of decline …
whole-brain radiation therapy (WBRT) is the standard therapy, it may have a risk of decline …
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
CH Chiu, CM Tsai, YM Chen, SC Chiang, JL Liou… - Lung cancer, 2005 - Elsevier
Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …
The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis
WY Li, TT Zhao, HM Xu, ZN Wang, YY Xu, Y Han… - BMC cancer, 2019 - Springer
Background The brain is a common site for metastasis in non-small-cell lung cancer
(NSCLC). This study was designed to evaluate the relationship between the mutational of …
(NSCLC). This study was designed to evaluate the relationship between the mutational of …
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs
T Kawamura, A Hata, J Takeshita, S Fujita… - Cancer Chemotherapy …, 2015 - Springer
Background After initial response to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), approximately one-third of patients develop central nervous system …
inhibitors (EGFR-TKIs), approximately one-third of patients develop central nervous system …
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy
T Masuda, N Hattori, A Hamada, H Iwamoto… - Cancer chemotherapy …, 2011 - Springer
Purpose We have treated patients with non-small-cell lung cancer (NSCLC) who developed
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …